05:51 AM EST, 11/09/2026 (MT Newswires) -- AcuCort (ACUC.ST) granted Kye Pharmaceuticals the exclusive rights to register, market, distribute, and sell Zeqmelit, its rapidly dissolving dexamethasone oral film, in Canada. The Swedish pharmaceutical company will receive upfront and milestone payments, product supply revenue, and net sales-based royalties as part of the license and distribution agreement, according to a Monday release. Regulatory submission is targeted for early 2027, and commercial launch is expected in 2028, subject to marketing authorization from Health Canada. Zeqmelit is indicated for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for patients with COVID-19 requiring supplemental oxygen therapy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.